Regen BioPharma, Inc. (RGBP)
OTCMKTS · Delayed Price · Currency is USD
0.0060
+0.0010 (20.00%)
At close: Jan 16, 2026
Regen BioPharma Revenue
In the fiscal year ending September 30, 2025, Regen BioPharma had annual revenue of $236.56K. Regen BioPharma had revenue of $59.37K in the quarter ending September 30, 2025.
Revenue
236.56K
Revenue Growth
n/a
P/S Ratio
2.74
Revenue / Employee
236.56K
Employees
1
Market Cap
648.33K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 236.56K | 1.00 | - |
| Sep 30, 2024 | 236.56K | - | - |
| Sep 30, 2023 | 236.56K | 1.04K | 0.44% |
| Sep 30, 2022 | 235.52K | 64.32K | 37.57% |
| Sep 30, 2021 | 171.19K | 61.19K | 55.63% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
Regen BioPharma News
- 2 months ago - Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. - Accesswire
- 6 months ago - Goldman Small Cap Research Publishes New Research Report on Regen BioPharma, Inc. - Accesswire
- 1 year ago - Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™ - GlobeNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time - GlobeNewsWire
- 1 year ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024 - PRNewsWire
- 1 year ago - Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024 - PRNewsWire
- 2 years ago - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024 - PRNewsWire